Becton Dickinson ramps upsyringe production amid demanddriven by China quality concerns

BD’s North Canaan plant has increased its output of syringes by more than 40% to meet the needs of U.S. healthcare customers after the FDA launched an ongoing investigation into quality issues with plastic syringes made in China.

Provided

Becton Dickinson ramps upsyringe production amid demanddriven by China quality concerns

NORTH CANAAN, Conn. — Becton, Dickinson and Company (BD) has ramped up its production of syringes at its North Canaan plant in response to quality issues with plastic syringes imported from China which were uncovered late last year by the U.S. Food and Drug Administration (FDA).

BD, a leading global medical technology company and Northwest Connecticut’s largest employer, responded to the FDA’s recommendation that consumers, healthcare providers and healthcare facilities transition away from plastic syringes made in China by increasing its domestic manufacturing of syringes at the company’s Connecticut and Nebraska facilities.

Since January, BD’s 385,000-square-foot North Canaan plant has increased its output of syringes “by over 40% to meet the needs of U.S. healthcare customers,” according to Fallon McLoughlin, director of public relations and corporate communications for the Franklin Lakes, N.J.-based company.

“BD has achieved this increase by driving operational efficiencies and relocating some production lines from other BD plants,” said McLoughin.

“We’ve added over 100 full-time associates in the last year, and currently have more than 500 full-time associates and nearly 50 contingent associates,” she said of the North Canaan site, which began its operations in 1961 with eight employees at a 25,000-square-foot facility.

BD draws its employees from throughout Northwest Connecticut and neighboring New York.

McLaughlin noted that its Connecticut plant primarily manufactures small-size syringes, and syringe and needle combination products that are “critical to the delivery of healthcare.”

Operations take place around the clock, producing more than 2 billion medical devices each year that are sold in every region worldwide.

Responding to consumer needs

In March, Eric Borin, president of BD Medication Delivery Solutions, announced a statement saying: “BD has the capacity to support additional syringe demand and is further increasing U.S. production to help ensure continuity of patient care.”

Since the initial FDA safety communication in November 2023, he noted, “BD has increased domestic manufacturing of syringes in our Nebraska and Connecticut facilities to respond to customer needs. Ensuring the safety and quality of our products is the top priority at BD.”

Borin further noted at the time that “The latest FDA safety communication does not include any BD syringes. Over our more than 125-year history, we have served the health care system’s need for essential high quality medical products, including manufacturing 2 billion additional syringes and needles to support the global pandemic response to COVID-19.”

Syringe manufacturers in China cited

In late November 2023, the FDA announced its probe into reports of leaks, breakages and other quality problems with plastic syringes manufactured in China “that are used for injecting fluids into or withdrawing fluids from, the body,” according to the health regulator.

On March 14, the FDA issued an update on warning letters sent to three entities: Jiangsu Shenli Medical Production Co. Ltd, Medline Industries, LP and Sol-Millennium Medical Inc., describing violations related to the “sale and distribution of unauthorized plastic syringes that had not been cleared or approved by the FDA,” according to a new release.

“In addition, we are actively evaluating quality issues and performance testing failures with plastic syringes made by Jiangsu Caina Medical Co Ltd., a China-based manufacturer sited in the warning letter issued to Medline Industries, LP. The FDA will take additional steps as appropriate,” the FDA stated.

In its August 16 update, the FDA continued to recommend that healthcare providers “use syringes not manufactured in China, if possible.

“At this time, glass syringes, pre-filled syringes or syringes used for topical purposes are not included. If you only have syringes manufactured in China, then continue to use them as needed until you are able to use alternative syringes and closely monitor for leaks, breakage and other problems,” the FDA announced.

In March, BD was named to Fortune’s 2024 list of America’s Most Innovative Companies, and in September, the company announced that it had been named to TIME’s 2024 list of the World’s Best Companies based on employee feedback.

BD’s operations in North Canaan have also been recognized by the U.S. Environmental Protection Agency for achieving the Energy Star Challenge for Industry for energy reduction. The site is a landfill-free site where waste is reduced, recycled or converted into energy.

Latest News

Participants at annual conference encouraged to ThinkDifferently by respecting evolving etiquette norms

Top row (left to right): Panelist Shadei Williams; Dana Hopkins, Dutchess County All Abilities Program Director; panelist Johnny Vacca; Dutchess County Executive Sue Serino. Bottom row: (left to right): Panelist Wayne Robinson; panelist Tracy Wallace; panelist Samantha Van Alstyne

Provided

HYDE PARK, N.Y. — On Thursday, Dec. 5, the annual ThinkDifferently conference was held at the Henry A. Wallace Visitor and Educational Center in Hyde Park, New York. The conference strived to enlighten participants on evolving protocols for addressing and collaborating with individuals with challenges.

Hosted by Dana Hopkins, program director of All Abilities at the Department of Behavioral and Community Health, ThinkDifferently is an initiative first launched in 2015 by former county executive Marc Molinaro with a goal to provide services to individuals with varying abilities and guidance for others such as businesses and communities to help create a more inclusive society.

Keep ReadingShow less
Shooting the breeze with Christopher Little

Martin Tandler

Little with his dog, Ruby.

"What I really feel lucky about is having had the chance to meet and photograph so many people who had a real impact on our lives,” said Christopher Little whose new memoir, “Shooting the Breeze: Memories of a Photojournalist” was just released. The book is as eclectic and colorful as the man himself and offers an intimate look into Little’s globe-trotting career spent behind the lens, capturing some of the most iconic figures, events, and human stories of the past half-century.

In 2021, the Dolph Briscoe Center for American History at The University of Texas acquired Little’s photographic archive.

Keep ReadingShow less
Cold Spring, a not-so-hidden Hudson Valley gem

“Cold Spring, NY” depicts life in a notable Hudson River town with a rich history and much natural beauty.

Krista A. Briggs

According to Alissa Malnati, co-creator of the new coffee table tome, “Cold Spring, NY”, after twenty-five years in the urban jungle, it was time to go in search of a cure for the angst which, for some, can come with metropolitan living. “My husband and I were soul sick,” explained Malnati of the couple’s move to Cold Spring, a Hudson River town located in leafy Putnam County. “We were seeking restoration and quiet, and to be in nature, away from the hustle and bustle of the city.”

The time was right for a move in 2021. The Malnatis relocated from busy Brooklyn to a tranquil mountaintop abode which allowed them to decompress without the intrusion of cell phones and ceaseless city noise. With the shift to the Hudson Valley, Alissa, a writer and fashion executive, and her husband, Will, a podcaster and television producer, found the peace they were searching for in Cold Spring, a semi-rural town known for its boutiques, antique shops, and world-class hiking trails.

Keep ReadingShow less